St. Jude looks beyond blood pressure for benefits of renal denervation

February 15, 2013 by MassDevice staff

Medical device company St. Jude Medical launches a landmark study of its Enlightn renal denervation in order to find out whether the nerve ablating treatment has unexpected health benefits beyond lowering high blood pressure.

St. Jude Medical's EnliGHTen renal denervation system

St. Jude Medical (NYSE:STJ) is aiming to take its renal denervation therapy a step further, looking for signs that the minimally invasive treatment improves health beyond lowering high blood pressure in patients with uncontrolled hypertension.

The company's new Enlightnment trial is looking for long-term effects of renal denervation therapy, hoping to find out whether it reduces a patient's risk of major cardiovascular events.

Sign up to get our free newsletters delivered right to your inbox.

"To date, the renal denervation studies that have been conducted only looked at reducing blood pressure in patients with uncontrolled or resistant hypertension," principal investigator Professor Michael Böhm said in prepared remarks. "What we need to know is if this minimally invasive approach for treating hypertension also correlates to a reduction in major cardiac events such as heart attack, stroke and death, which are the primary risks for patients whose blood pressure is not well controlled."

Comments